v3.26.1
Revenue Recognition
6 Months Ended
Jun. 30, 2026
Accounting Policies [Abstract]  
Revenue Recognition
5.
Revenue Recognition

Disaggregation of Revenue

Revenue for the three and six months ended June 30, 2026 and 2025 was as follows:

 

 

Three Months Ended June 30,

 

 

Six Months Ended June 30,

 

 

 

2026

 

 

2025

 

 

2026

 

 

2025

 

 

 

(Amounts in thousands)

 

Product revenue

 

$

204,085

 

 

$

182,329

 

 

$

398,296

 

 

$

351,466

 

Royalty and other revenue

 

 

43

 

 

 

37

 

 

 

87

 

 

 

72

 

Total revenue

 

$

204,128

 

 

$

182,366

 

 

$

398,383

 

 

$

351,538

 

When disaggregating revenue, the Company considered all of the economic factors that may affect its revenues. Because its revenues are from bioprocessing customers, there are no differences in the nature, timing and uncertainty of the Company’s revenues and cash flows from any of its product lines. However, given that the Company’s revenues are generated in different geographic regions, factors such as regulatory and geopolitical factors within those regions could impact the nature, timing and uncertainty of the Company’s revenues and cash flows.

Disaggregated revenue from contracts with customers by geographic region and revenue from significant customers can be found in Note 13, “Segment Reporting.” For more information regarding product revenue, see Note 7, “Revenue Recognition” included in Part II, Item 8, “Financial Statements and Supplementary Data to the Company's Form 10-K.

Contract Balances from Contracts with Customers

The following table provides information about receivables and deferred revenue from contracts with customers as of June 30, 2026 and December 31, 2025:

 

 

June 30,

 

 

December 31,

 

 

 

2026

 

 

2025

 

 

 

(Amounts in thousands)

 

Balances from contracts with customers only:

 

 

 

 

 

 

Accounts receivable

 

$

157,710

 

 

$

158,587

 

Deferred revenue (included in accrued liabilities and other noncurrent liabilities in the condensed consolidated balance sheets)

 

$

22,652

 

 

$

16,152

 

 

During the six months ended June 30, 2026, the Company recognized $9.6 million of revenue that was deferred and included within accrued liabilities and other noncurrent liabilities as of December 31, 2025. During the six months ended June 30, 2025, the Company recognized $8.5 million of revenue that was deferred and included within accrued liabilities and other noncurrent liabilities as of December 31, 2024.

The timing of revenue recognition, billings and cash collections results in the accounts receivable and deferred revenue balances on the Company’s condensed consolidated balance sheets.